Bristol-Myers Squibb Company (ETR:BRM)
Germany
· Delayed Price · Currency is EUR | Market Cap | 110.73B |
| Revenue (ttm) | 46.65B |
| Net Income (ttm) | -8.64B |
| Shares Out | n/a |
| EPS (ttm) | -4.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 2.26 (4.13%) |
| Ex-Dividend Date | Apr 4, 2025 |
| Volume | 59 |
| Average Volume | 1,473 |
| Open | 54.57 |
| Previous Close | 54.84 |
| Day's Range | 54.57 - 54.71 |
| 52-Week Range | 36.42 - 58.79 |
| Beta | 0.44 |
| RSI | 45.32 |
| Earnings Date | Apr 24, 2025 |
About ETR:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Bristol Myers Squibb gets positive CHMP opinion for neoadjuvant Opdivo and chemotherapy
Bristol Myers Squibb gets CHMP positive opinion for Opdivo in multiple solid tumors
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell L...
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
Recommendation is based primarily on results from the Phase 3 CheckMate -67T trial which demonstrated noninferiority in the co-primary endpoints of C avgd28 and C minss and consistent efficacy in the ...
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of a new Opdivo (nivolum...
2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results
Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generat...
Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold
Bristol Myers Stock: This Covered Call Could Enhance Your Return Beyond A 4% Dividend Yield
The sold call produces a 9.83% annualized yield in addition to the dividend.
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
The Association of the British Pharmaceutical Industry (ABPI) is urging ministers to address excessive levies on manufacturers to ensure the sector remains competitive globally. The life sciences indu...
Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy
Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.
Multiple Myeloma Market to Witness Substantial Growth -- Key Trends and Forecasts of Different Reports for the Next Decade | DelveInsight
The multiple myeloma market is expected to grow in the upcoming years, owing to a rise in incident cases, label expansion and penetration of current therapies in earlier lines, high adoption of newer ...
Bristol-Myers Squibb: Why I'm Still Bullish
JPMorgan says own this drug stock. It's one Jim Cramer is itching to buy again
The Club remains optimistic about Bristol Myers and shares JPMorgan's enthusiasm about Cobenfy.
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
On Friday, the European Commission (EC) approved Bristol Myers Squibb & Co ‘s (NYSE: BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy...
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 2seventy bio, Inc. (NasdaqGS: TSVT) to Bristol...
Bristol Myers Squibb gets EC nod for expanded use of Breyanzi
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has granted approval to Breyanzi(lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR)...
Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025
Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2025 on Thursday, April 24, 2025. Company executives will review financial results with the investment community during ...
Bristol-Myers Squibb Company (BMY) Presents at Leerink Partners 2025 Global Healthcare Conference (Transcript)
Bristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy Pioneer
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a good deal for BMY or TSVT.
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders
The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myers Squibb. Click here to learn how to...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating 2seventy bio, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - March 11, 2025) - Rigrodsky Law, P.A. is investigating 2seventy bio, Inc. ("2seventy") (NASDAQ: TSVT) regarding possible breaches of fiduciary duties and other ...
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Bristol Myers Squibb to acquire 2seventy Bio for $5.00 ... Full story available on Benzinga.com
TSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 2seventy bio, Inc. (NASDAQ: TSVT) to Bristol Myers Squibb for $5.00 per share is fair to 2seventy shareholders. Halp...